1. Home
  2. BETR vs TLSI Comparison

BETR vs TLSI Comparison

Compare BETR & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Better Home & Finance Holding Company

BETR

Better Home & Finance Holding Company

N/A

Current Price

$13.55

Market Cap

334.8M

Sector

Finance

ML Signal

N/A

Logo TriSalus Life Sciences Inc.

TLSI

TriSalus Life Sciences Inc.

N/A

Current Price

$5.27

Market Cap

270.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BETR
TLSI
Founded
2014
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
334.8M
270.2M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
BETR
TLSI
Price
$13.55
$5.27
Analyst Decision
Buy
Strong Buy
Analyst Count
1
1
Target Price
$40.00
$7.00
AVG Volume (30 Days)
677.0K
204.0K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
20.88
N/A
EPS
N/A
N/A
Revenue
$164,872,000.00
$45,151,000.00
Revenue This Year
$55.02
$35.45
Revenue Next Year
$65.66
$37.58
P/E Ratio
N/A
N/A
Revenue Growth
51.97
53.41
52 Week Low
$13.18
$2.20
52 Week High
$94.06
$7.95

Technical Indicators

Market Signals
Indicator
BETR
TLSI
Relative Strength Index (RSI) 33.79 60.56
Support Level N/A $3.77
Resistance Level $28.72 $5.58
Average True Range (ATR) 2.31 0.36
MACD -0.44 0.02
Stochastic Oscillator 1.89 59.57

Price Performance

Historical Comparison
BETR
TLSI

About BETR Better Home & Finance Holding Company

Better Home & Finance Holding Co is a technology-enabled homeownership company that provides mortgage, home equity, and related services through a digital platform. The company operates through two reportable segments: Home Finance, which focuses on residential mortgage origination, including purchase, refinance, and home equity products, generating revenue mainly from loan sales; and Banking, which, through its U.K. subsidiary Birmingham Bank, offers a range of financial products and services to consumers and small businesses. It generates the majority of its revenue from the Home Finance segment.

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Share on Social Networks: